Eli Lilly partners at CRUK tackle the first human study of a new p53-targeted cancer drug
Cancer Research UK has kicked off an early-stage study of a new Eli Lilly cancer drug that will try to hit the ever-elusive target of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
